Belgium plans to temporarily ban the drug Ozempic (semaglutide) for the treatment of obesity. The decision is aimed at preserving the drug's availability for patients with type 2 diabetes.
- [Last month] we appealed to doctors to use this drug only in patients with type 2 diabetes. Today we see that this strategy has not worked," said Franck Vandenbroucke, Belgian Health Minister. - I know that this drug can also be useful in people suffering from pathological obesity, so, of course, we need to talk about it. But I am convinced that we now need to send a stronger message, because simple recommendations are not enough," the ministry chief added.
<...Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
